JP2019518732A5 - - Google Patents

Download PDF

Info

Publication number
JP2019518732A5
JP2019518732A5 JP2018558728A JP2018558728A JP2019518732A5 JP 2019518732 A5 JP2019518732 A5 JP 2019518732A5 JP 2018558728 A JP2018558728 A JP 2018558728A JP 2018558728 A JP2018558728 A JP 2018558728A JP 2019518732 A5 JP2019518732 A5 JP 2019518732A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
formula
sleep
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018558728A
Other languages
English (en)
Japanese (ja)
Other versions
JP6888026B2 (ja
JP2019518732A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/032228 external-priority patent/WO2017197160A1/en
Publication of JP2019518732A publication Critical patent/JP2019518732A/ja
Publication of JP2019518732A5 publication Critical patent/JP2019518732A5/ja
Priority to JP2021084719A priority Critical patent/JP7150096B2/ja
Application granted granted Critical
Publication of JP6888026B2 publication Critical patent/JP6888026B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018558728A 2016-05-12 2017-05-11 概日リズム睡眠障害群を治療する方法 Active JP6888026B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021084719A JP7150096B2 (ja) 2016-05-12 2021-05-19 概日リズム睡眠障害群を治療する方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662335599P 2016-05-12 2016-05-12
US201662335611P 2016-05-12 2016-05-12
US62/335,611 2016-05-12
US62/335,599 2016-05-12
US201662413976P 2016-10-27 2016-10-27
US62/413,976 2016-10-27
US201662414606P 2016-10-28 2016-10-28
US201662414599P 2016-10-28 2016-10-28
US62/414,606 2016-10-28
US62/414,599 2016-10-28
PCT/US2017/032228 WO2017197160A1 (en) 2016-05-12 2017-05-11 Methods of treating circadian rhythm sleep disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021084719A Division JP7150096B2 (ja) 2016-05-12 2021-05-19 概日リズム睡眠障害群を治療する方法

Publications (3)

Publication Number Publication Date
JP2019518732A JP2019518732A (ja) 2019-07-04
JP2019518732A5 true JP2019518732A5 (https=) 2020-06-18
JP6888026B2 JP6888026B2 (ja) 2021-06-16

Family

ID=58745465

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018558728A Active JP6888026B2 (ja) 2016-05-12 2017-05-11 概日リズム睡眠障害群を治療する方法
JP2021084719A Active JP7150096B2 (ja) 2016-05-12 2021-05-19 概日リズム睡眠障害群を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021084719A Active JP7150096B2 (ja) 2016-05-12 2021-05-19 概日リズム睡眠障害群を治療する方法

Country Status (16)

Country Link
US (2) US11096941B2 (https=)
EP (2) EP4056180A1 (https=)
JP (2) JP6888026B2 (https=)
KR (2) KR102511855B1 (https=)
CN (1) CN109640998A (https=)
AU (3) AU2017264871B2 (https=)
CA (1) CA3022068A1 (https=)
ES (1) ES2904625T3 (https=)
IL (2) IL291791B2 (https=)
MX (1) MX379318B (https=)
MY (1) MY199382A (https=)
RU (1) RU2763493C2 (https=)
SG (1) SG11201809527UA (https=)
TW (1) TWI795359B (https=)
WO (1) WO2017197160A1 (https=)
ZA (1) ZA201807903B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11096941B2 (en) * 2016-05-12 2021-08-24 Eisai R&D Management Co.. Ltd. Methods of treating circadian rhythm sleep disorders
BR112021026291A2 (pt) * 2019-06-26 2022-03-03 Eisai R&D Man Co Ltd Lemborexant para tratar problemas de sono
JP2022538170A (ja) * 2019-06-26 2022-08-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 睡眠問題の治療のためのレンボレキサント
WO2020263253A1 (en) * 2019-06-26 2020-12-30 Moline Margaret Lemborexant for treating sleep issues
JP7573015B2 (ja) * 2019-09-13 2024-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 不眠症治療用医薬組成物
JP2023506025A (ja) * 2019-12-11 2023-02-14 テバ チェコ インダストリーズ エス.アール.オー. レンボレキサントの固体形態
MX2022008260A (es) * 2020-01-16 2022-08-04 Eisai R&D Man Co Ltd Sustancia farmacologica de lemborexant y composicion medicinal que la comprende.
CN111450076A (zh) * 2020-05-25 2020-07-28 安徽省逸欣铭医药科技有限公司 一种Lemborexant软胶囊组合物及其制备方法
CN114159568B (zh) * 2020-09-11 2025-08-01 北京原基华毅生物科技有限公司 Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用
WO2023007320A1 (en) * 2021-07-26 2023-02-02 Eisai R&D Mangement Co., Ltd. Lemborexant for use in methods of treating irregular sleep-wake rhythm disorder and circadian rhythm sleep disorders associated with neurodegenerative diseases
CN116421605B (zh) * 2022-01-04 2024-08-02 中国科学院脑科学与智能技术卓越创新中心 Isx-9在治疗衰老相关的昼夜节律幅度下降和睡眠障碍方面的应用
WO2024064897A1 (en) 2022-09-23 2024-03-28 Eisai R&D Management Co., Ltd. Methods of reducing neurodegeneration associated with neurodegenerative diseases
CN121646412A (zh) 2023-08-08 2026-03-10 株式会社明治 昼夜节律的调整

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06009377A (es) * 2004-02-20 2007-03-07 Lifescape Biosciences Inc Composiciones y metodos para regulacion del sueno.
ATE458740T1 (de) * 2006-08-28 2010-03-15 Actelion Pharmaceuticals Ltd 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
AU2011304285B2 (en) 2010-09-22 2015-01-29 Eisai R&D Management Co., Ltd. Cyclopropane compound
CA2863413A1 (en) * 2012-02-07 2013-08-15 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
ES2843952T3 (es) 2014-10-23 2021-07-21 Eisai R&D Man Co Ltd Composiciones para tratar el insomnio
US11096941B2 (en) * 2016-05-12 2021-08-24 Eisai R&D Management Co.. Ltd. Methods of treating circadian rhythm sleep disorders

Similar Documents

Publication Publication Date Title
JP2019518732A5 (https=)
IL291791B1 (en) Methods for treating sleep timing disorders
Sheta et al. Intranasal dexmedetomidine vs midazolam for premedication in children undergoing complete dental rehabilitation: a double‐blinded randomized controlled trial
JP2020528075A5 (https=)
Beaudin et al. Impact of obstructive sleep apnoea and intermittent hypoxia on cardiovascular and cerebrovascular regulation
JP2025024102A (ja) 神経障害および神経障害の処置方法
JP2016147915A5 (https=)
Miano et al. NREM sleep instability changes following rapid maxillary expansion in children with obstructive apnea sleep syndrome
JP2021512098A5 (https=)
JP2017537985A5 (https=)
HRP20200180T1 (hr) Derivati (aza-)izokinolinona
JP2015532296A5 (https=)
JP2019516756A5 (https=)
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法
Erdil et al. Effects of sevoflurane or ketamine on the QTc interval during electroconvulsive therapy
Hooshmand et al. Klüver-Bucy syndrome: successful treatment with carbamazepine
Hassan Dexmedetomidine versus ketofol for moderate sedation in Endoscopic Retrograde Cholangiopancreatography (ERCP) comparative study
DOP2022000093A (es) Inhibidores de adrenoreceptor adrac2
JP2015521643A5 (https=)
JP2010529130A5 (https=)
RU2019132951A (ru) Применение обратного агониста h3r для лечения расстройства сна при сменной работе
JP2025530256A (ja) ストレス関連障害の治療のためのmdmaの使用
JP2013528627A5 (https=)
JP2014224108A5 (https=)
CN105111126A (zh) 靛红衍生物6-溴-2,3-二氧代吲哚啉-n-卤素取代苯乙酰胺和制备方法及其应用